Hims & Hers Health, Inc. $HIMS Shares Sold by Russell Investments Group Ltd.

Russell Investments Group Ltd. decreased its holdings in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 80.8% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 26,443 shares of the company’s stock after selling 110,939 shares during the period. Russell Investments Group Ltd.’s holdings in Hims & Hers Health were worth $781,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the business. UMB Bank n.a. lifted its position in Hims & Hers Health by 247.5% in the first quarter. UMB Bank n.a. now owns 1,310 shares of the company’s stock valued at $39,000 after purchasing an additional 933 shares during the period. Larson Financial Group LLC lifted its position in Hims & Hers Health by 47.7% in the first quarter. Larson Financial Group LLC now owns 1,419 shares of the company’s stock valued at $42,000 after purchasing an additional 458 shares during the period. Fifth Third Bancorp lifted its position in Hims & Hers Health by 165.4% in the first quarter. Fifth Third Bancorp now owns 1,542 shares of the company’s stock valued at $46,000 after purchasing an additional 961 shares during the period. Tsfg LLC acquired a new stake in Hims & Hers Health in the first quarter valued at about $46,000. Finally, N.E.W. Advisory Services LLC acquired a new stake in Hims & Hers Health in the first quarter valued at about $49,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Wall Street Analyst Weigh In

HIMS has been the subject of a number of recent analyst reports. UBS Group set a $30.00 price objective on shares of Hims & Hers Health in a research report on Monday, June 23rd. Truist Financial reduced their price target on shares of Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a research report on Monday, August 18th. Piper Sandler reiterated a “neutral” rating and set a $39.00 price target (up from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Morgan Stanley reiterated an “equal weight” rating and set a $40.00 price target on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Finally, Wall Street Zen downgraded shares of Hims & Hers Health from a “buy” rating to a “hold” rating in a research report on Monday, July 28th. Two research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Reduce” and an average target price of $38.92.

Hims & Hers Health Trading Down 4.0%

Shares of HIMS opened at $42.36 on Friday. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. The firm has a 50 day simple moving average of $49.98 and a 200-day simple moving average of $45.82. Hims & Hers Health, Inc. has a 1-year low of $13.47 and a 1-year high of $72.98. The stock has a market cap of $9.57 billion, a price-to-earnings ratio of 52.95, a price-to-earnings-growth ratio of 2.98 and a beta of 2.08.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The business had revenue of $544.83 million for the quarter, compared to analysts’ expectations of $550.06 million. During the same period last year, the business earned $0.06 earnings per share. The company’s revenue for the quarter was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 2,100 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, July 24th. The shares were sold at an average price of $57.52, for a total value of $120,792.00. Following the completion of the sale, the insider directly owned 278,654 shares of the company’s stock, valued at approximately $16,028,178.08. The trade was a 0.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Patrick Harrison Carroll sold 60,000 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $53.58, for a total transaction of $3,214,800.00. Following the completion of the sale, the insider directly owned 169,940 shares of the company’s stock, valued at $9,105,385.20. The trade was a 26.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,395,428 shares of company stock worth $71,753,898 in the last three months. 13.71% of the stock is currently owned by company insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.